Charles Schwab Investment Management Inc. Has $108.30 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Charles Schwab Investment Management Inc. cut its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,252,353 shares of the biotechnology company's stock after selling 21,267 shares during the period. Charles Schwab Investment Management Inc. owned 1.14% of Exelixis worth $108,303,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after acquiring an additional 330 shares during the period. Schechter Investment Advisors LLC grew its position in Exelixis by 6.3% in the 4th quarter. Schechter Investment Advisors LLC now owns 13,705 shares of the biotechnology company's stock worth $456,000 after purchasing an additional 816 shares during the last quarter. Grandfield & Dodd LLC increased its stake in shares of Exelixis by 81.9% in the fourth quarter. Grandfield & Dodd LLC now owns 21,866 shares of the biotechnology company's stock valued at $728,000 after purchasing an additional 9,846 shares during the period. LGT Fund Management Co Ltd. acquired a new stake in shares of Exelixis in the fourth quarter valued at approximately $2,525,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Exelixis by 958.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,942 shares of the biotechnology company's stock worth $99,000 after buying an additional 2,664 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently commented on EXEL shares. Stifel Nicolaus raised their target price on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research report on Wednesday, February 12th. StockNews.com raised Exelixis from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 19th. Bank of America downgraded shares of Exelixis from a "buy" rating to a "neutral" rating and upped their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Finally, Stephens restated an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $37.24.

Insider Activity

In related news, Director Mary C. Beckerle sold 12,210 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by corporate insiders.

Exelixis Trading Up 0.6 %

Shares of EXEL traded up $0.22 during midday trading on Wednesday, hitting $37.15. The stock had a trading volume of 1,786,384 shares, compared to its average volume of 2,084,946. The business has a 50-day simple moving average of $35.18 and a two-hundred day simple moving average of $32.29. The firm has a market cap of $10.40 billion, a P/E ratio of 21.00, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.